RACIAL/ETHNIC DISPARITIES AND OUTCOMES OF PATIENTS WITH PANCREATIC CANCER- DATA FROM A SAFETY-NET HOSPITAL gsirnioti@gmail.com

211-06

RACIAL/ETHNIC DISPARITIES AND OUTCOMES OF PATIENTS WITH PANCREATIC CANCER- DATA FROM A SAFETY-NET HOSPITAL

8

United States

Oral or Poster

Our study aimed to describe the racial/ethnic disparities in the presentation and prognosis of pancreatic cancer, in addition to assessing factors associated with survival.

We conducted a retrospective analysis of pancreatic cancer patients that presented to BUHMC from 2013 to 2022. Data was identified from the tumor registry of the hospital and the Electronic Medical Record. For our statistical analysis, African Americans were compared with other racial groups. Cox proportional hazards models were used to assess factors associated with increased mortality risk following diagnosis. A p < 0.05 was considered significant.

We identified 122 patients during the defined period. The median age was 68 years (IQR 59-77) and 51.6% of patients were male. Of the examined population, 93 (76.2%) were African American, 18 (14.8%) Hispanic/Latino, 7 (5.7%) non-Hispanic White and 4 (3.3%) other/mixed ethnicity. The median follow-up was 4.95 months (IQR 1.84-14.89). When comparing African Americans with other racial groups, no significant difference was found in the stage, location, or treatment of pancreatic cancer. African Americans had higher 3-year mortality rate compared to other ethnic groups (p<0.01). Germline genetic testing was performed only in 8 (6.6%) of the patients, one of which was positive for BRCA1 mutation.

No statistically significant difference was noted in stage, location and treatment modalities between races in our cohort. African Americans had worse survival compared to other ethnic groups. Germline genetic testing was largely underutilized in our population.